VEGFA and B-cell chronic lymphocytic leukemia: Elevated VEGF and hypoxia-inducible factor 1 (HIF-1) production is representative for proangiogenic profile and therefore additional CLL cell survival and resistance to rituximab/alemtuzumab [71].